Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

When genomic and standard test results diverge: implications for breast cancer patients' preference for chemotherapy.

Breast cancer research and treatment - 1 Sept 2009

Brewer Noel T, Edwards Alrick S, O'Neill Suzanne C, Tzeng Janice P, Carey Lisa A, Rimer Barbara K

Abstract excerpt

PURPOSE: We examined how women incorporate potentially differing genomic and standard assessments of breast cancer recurrence risk into chemotherapy decisions. METHODS: 165 women previously treated for early-stage breast cancer indicated their interest in chemotherapy regimens to prevent recurrence of breast cancer in response to six hypothetical vignettes that presented breast cancer recurrence risk estimates...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Decision Making

Share to Genetic Testing

Share to Neoplasm Recurrence, Local

Share to Patient Satisfaction

Share to Risk Factors

Source

Identifiers

PMID: 18785002
DOI: 10.1007/s10549-008-0175-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

When genomic and standard test results diverge: implications for breast cancer patients' preference for chemotherapy.PMID 18785002Read ↗

Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy.Semantic proximity Read ↗

Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score.Semantic proximity Read ↗

Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.Semantic proximity Read ↗

Health literacy and cancer risk perception: implications for genomic risk communication.Semantic proximity Read ↗

Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer.Semantic proximity Read ↗

Metastatic breast cancer patient perception of somatic tumor genomic testingSemantic proximity Read ↗

Metastatic breast cancer patient perception of somatic tumor genomic testingSemantic proximity Read ↗

Preferences for learning different types of genome sequencing results among young breast cancer patients: Role of psychological and clinical factors.Semantic proximity Read ↗

The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy.Semantic proximity Read ↗

21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.Semantic proximity Read ↗

Metastatic breast cancer patient perceptions of somatic tumor genomic testing.Semantic proximity Read ↗

Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.